Chronic Obstructive Pulmonary Disease (COPD) Biologics Market Set for Strong Growth to US$ 1,678.90 Million by 2033, Led by North America's 41.8% Market Share | Key Players - Sanofi, Regeneron Pharmaceuticals, GSK

The Chronic Obstructive Pulmonary Disease (COPD) Biologics Market reached US$ 604.70 million in 2024 and is expected to reach US$ 1,678.90 million by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033.

The market is experiencing steady growth due to the increasing prevalence of severe COPD, rising awareness of targeted biologic therapies, and expanding research focused on inflammatory pathways associated with chronic respiratory diseases. Advances in precision medicine and improved diagnostic capabilities are also supporting the adoption of biologic treatments for patients with uncontrolled disease despite standard therapies.

Industry participants are focusing on developing novel biologics targeting specific inflammatory biomarkers to improve treatment outcomes and reduce exacerbation rates. Strategic collaborations, expanding clinical pipelines, and investments in next-generation respiratory biologics are expected to strengthen market competitiveness while addressing the growing demand for personalized COPD management.

Get a Free Sample PDF of this Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/chronic-obstructive-pulmonary-disease-copd-biologics-market?ram

Key Industry Developments

United States:
✅ June 2026: Amgen continued advancing tezepelumab (Tezspire) for COPD, with the company highlighting ongoing Phase III development evaluating the biologic in patients with moderate-to-very severe COPD with type 2 inflammation. The program remained one of the leading late-stage biologic R&D efforts targeting COPD beyond inhaled therapies.

✅ January 2026: Regeneron Pharmaceuticals & Sanofi continued the U.S. commercial expansion of Dupixent (dupilumab) following its FDA approval for COPD, supporting physician adoption and reinforcing the first biologic treatment option for eligible COPD patients with type 2 inflammation.

✅ October 2025: Regeneron Pharmaceuticals & Sanofi advanced post-launch clinical and medical education initiatives for Dupixent in COPD, expanding real-world adoption efforts and strengthening evidence generation following the landmark U.S. approval.

Japan:
✅ June 2026: GSK Japan updated its development pipeline, confirming depemokimab (GSK3511294) remained in Phase III development for COPD, highlighting continued investment in long-acting IL-5 biologic therapy for respiratory diseases.

✅ December 2025: GSK Japan announced regulatory approval of depemokimab for severe asthma and chronic rhinosinusitis with nasal polyps. While not a COPD approval, the milestone strengthened GSK's biologics platform and supported future respiratory biologic development, including its ongoing COPD Phase III program.

✅ October 2025: GSK Japan continued late-stage clinical development activities for depemokimab in COPD, maintaining Japan as a key market supporting the biologic's global Phase III respiratory development program.

Strategic Acquisitions & Partnerships
✅ Sanofi & Regeneron - Ongoing Strategic Partnership (Existing Collaboration; No New Partnership Announced)
May, 2025
Sanofi and Regeneron announced Phase III AERIFY trial results for itepekimab, their jointly developed anti-IL-33 biologic for COPD. The companies confirmed they would jointly assess the data and discuss regulatory next steps, but this was not a new partnership or acquisition-it was a continuation of their long-standing collaboration.

✅ Sanofi & Regeneron - Expansion of Existing Respiratory Development Program (Existing Collaboration; No New Transaction)
April, 2025
Sanofi announced continued expansion of the existing Sanofi-Regeneron respiratory collaboration, including additional clinical studies of itepekimab in COPD and other respiratory diseases. The announcement described pipeline advancement only and did not involve a newly executed strategic partnership, acquisition, merger, or joint venture.

Key Players:
Sanofi | Regeneron Pharmaceuticals | GSK

Key Highlights: Top 5 Key Players in Chronic Obstructive Pulmonary Disease (COPD) Biologics Market 2026
-Sanofi: Expanded the global reach of Dupixent (dupilumab) by securing regulatory approvals for COPD, including Japan, making it the first biologic approved for COPD in multiple major markets. The therapy targets IL-4 and IL-13 pathways to reduce exacerbations in patients with type 2 inflammation.

-Regeneron Pharmaceuticals: Strengthened the clinical evidence for Dupixent (dupilumab) by presenting extensive Phase III COPD data at the ATS 2025 conference, highlighting improvements in lung function, quality of life, and reduced exacerbations across patients with type 2 inflammation.

-GSK: Advanced Nucala (mepolizumab) with FDA and European Commission approvals for eosinophilic COPD, making it the first monthly IL-5 biologic approved for this patient population. The MATINEE and METREX studies demonstrated significant reductions in moderate and severe exacerbations.

-AstraZeneca: Continued expanding its COPD biologics pipeline through Tezspire (tezepelumab) and other respiratory biologics, reporting encouraging Phase II COURSE trial outcomes in eosinophilic COPD and initiating plans for Phase III development to address unmet needs in severe COPD.

-Amgen: In collaboration with AstraZeneca, advanced Tezspire (tezepelumab) by presenting new COPD clinical data demonstrating reductions in exacerbations among patients with elevated eosinophil counts, reinforcing the biologic's potential beyond severe asthma into COPD management.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-obstructive-pulmonary-disease-copd-biologics-market?ram

Main Drivers and Trends Shaping the Future of the Chronic Obstructive Pulmonary Disease (COPD) Biologics Market
-Rising COPD Burden: Increasing prevalence of COPD, driven by smoking, air pollution, occupational exposure, and aging populations, is accelerating demand for advanced biologic therapies that address severe and uncontrolled disease.

-Advancements in Targeted Biologics: The development of monoclonal antibodies targeting inflammatory pathways such as IL-5, IL-4/IL-13, and TSLP is expanding personalized treatment options and improving clinical outcomes for eosinophilic COPD patients.

-Precision Medicine Adoption: Growing use of biomarker-based patient selection, including blood eosinophil counts, is enabling tailored biologic therapies with enhanced efficacy and reduced exacerbation rates.

-Market Hurdles: High biologic therapy costs, limited patient eligibility, reimbursement challenges, and the need for long-term clinical evidence on safety and effectiveness continue to restrain broader market adoption.

Regional Insights:
-North America: 41.8% (Largest share, driven by early adoption of biologic therapies such as dupilumab, strong reimbursement systems, high COPD diagnosis rates, and extensive clinical research activity.)

-Europe: 28.4% (Supported by well-established respiratory care networks, increasing use of targeted biologics, favorable reimbursement, and ongoing respiratory disease research across Germany, the UK, France, and Italy.)

-Asia Pacific: 20.9% (Fastest-growing region, fueled by rising COPD prevalence, expanding healthcare infrastructure, improving biologics accessibility, and growing investments in China, Japan, South Korea, and India.)

-Latin America: 5.3% (Growth supported by improving access to advanced respiratory therapies, increasing awareness of COPD management, and gradual expansion of specialty healthcare services.)

-Middle East & Africa: 3.6% (Driven by improving respiratory healthcare infrastructure, increasing diagnosis rates, and gradual adoption of innovative biologic therapies in major Gulf countries and South Africa.)

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-obstructive-pulmonary-disease-copd-biologics-market?ram

Market Segmentation Analysis:
-By Drug Class: Dupilumab Leads with First Approved COPD Biologic
Dupilumab represents the leading biologic segment, becoming the first biologic approved for COPD patients with type 2 inflammation characterized by elevated blood eosinophils. It reduces exacerbations and improves lung function in eligible patients with uncontrolled disease despite standard inhaled therapies. Mepolizumab is an emerging biologic targeting interleukin-5 (IL-5) for eosinophilic COPD, supported by clinical evidence demonstrating reduced exacerbation rates in selected patients. Its adoption is expected to grow as additional regulatory approvals and clinical guideline recommendations expand biologic treatment options.

-By Route of Administration: Subcutaneous Delivery Dominates
Subcutaneous administration is the primary route for COPD biologics due to its convenience, established safety profile, and suitability for long-term maintenance therapy. It enables administration in hospitals, specialty clinics, or at home for selected patients, improving treatment adherence while reducing the need for frequent hospital visits.

-By Distribution Channel: Hospital Pharmacies Lead Access
Hospital pharmacies remain the primary distribution channel, as COPD biologics require specialist prescribing, patient evaluation, and monitoring before initiation. Specialty pharmacies are expanding their role by providing biologic dispensing, patient education, adherence support, reimbursement assistance, and coordinated home-delivery services for eligible patients.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.